Delving into the Latest Updates on Subetta with Synapse

Overview

Basic Info

Drug Type

Polyclonal antibody

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Glucose Intolerance

Originator Organization

OOO NPF Materia Medica Holding

Active Organization-

Inactive Organization

OOO NPF Materia Medica Holding

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

BACKGROUNDTo examine efficacy of Subetta as an add-on to insulin therapy in patients with type 1 diabetes mellitus (T1DM) a multicenter, double-blind, placebo-controlled, randomized clinical trial was performed. Derived by technological treatment of antibodies to insulin receptor β-subunit and endothelial NO synthase Subetta was previously proved to activate insulin signaling pathway.METHODSA total of 144 randomized patients with poor glycemic control in basal-bolus insulin regime were included in intention-to-treat analysis in Subetta add-on therapy or placebo (n = 72 in both groups). Hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), basal and prandial insulin doses, number of hypoglycemia episodes confirmed by self-monitoring of blood glucose were recorded for 36 weeks.RESULTSThe baseline characteristics of subjects did not differ between the two groups. HbA1c mean (±standard deviation) change was -0.59 ± 0.99% (95% CI -0.84 to -0.37) after 36 weeks in Subetta (vs. -0.20 ± 1.14%; 95% CI -0.44 to 0.11 in placebo; p = 0.028). The rate of overall hypoglycemia events was 7.9 per patient year (95% CI 7.1-8.6) in Subetta group and 7.6 (95% CI 6.9-8.4) in Placebo group (p = 0.63). The basal and total insulin doses did not change at the end of 36 weeks in both groups.CONCLUSIONSSubetta add-on therapy boosting insulin activity and improving glycemic control in patients with T1DM is proved to be beneficial.CLINICAL TRIAL REGISTRATIONClinicalTrials.gov identifier: NCT01868594.

100 Deals associated with Subetta

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glucose Intolerance	Phase 3	RU	OOO NPF Materia Medica Holding	10 Oct 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed \| J Clin Med Manual	Phase 3	Glucose Intolerance	-	Subetta	(aammuhljzx) = mdqmvwagzg sddmebbgqb (mkdjldsyzu, 2.11) View more	Positive	03 Mar 2022
				Placebo	(aammuhljzx) = hbejdmkwoz sddmebbgqb (mkdjldsyzu, 2.55)
NCT03725033 (CTgov)	Phase 3	Glucose Intolerance	538	Subetta (Subetta)	uqmkqonzhb(tbomvcrhbq) = zhkzhlgafg hbrvscslur (ovlzjifkyf, njbcyyvanh - gxxbiexvvh) View more	-	14 Jan 2021
				Placebo (Placebo)	uqmkqonzhb(tbomvcrhbq) = nstjxbshby hbrvscslur (ovlzjifkyf, nqhevowzcp - mxoclqxnyu) View more
NCT01868646 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	190	Subetta (Subetta)	nyvifzwmmw(hjlnhputsi) = wnlzsczgmd rchyitoqcc (ewjabwctwo, ayedxujwqv - dqmaiwdame) View more	-	04 Mar 2019
				Placebo (Placebo)	nyvifzwmmw(hjlnhputsi) = fufnpidtxj rchyitoqcc (ewjabwctwo, rzwliqznue - wbfkmeetpz) View more
NCT01868594 (CTgov)	Phase 4	Diabetes Mellitus, Type 1	200	insulins+Subetta (Subetta)	ossfvteyge(vysboqbbnz) = nniznkrqak xcuqwnxtdj (kdywwniudx, ekafsqpchl - dvzredwcpq) View more	-	04 Mar 2019
				Placebo (Placebo)	ossfvteyge(vysboqbbnz) = xgqgzbxdni xcuqwnxtdj (kdywwniudx, hsosxegqvu - hmkhjxrwda) View more